Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Condition: Muscle-invasive Bladder Cancer
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT02462239
Sponsor: Ontario Clinical Oncology Group (OCOG)
- Age: minimum 18 Years maximum N/A
- Gender: All
- Men and women with newly diagnosed muscle-invasive high grade urothelial carcinoma of the bladder (TNM stage T2a-T4a, N0-3, M0), who are eligible for either radical cystectomy or radiotherapy-based bladder conservation.
- Being considered for treatment of curative intent.
- Age < 18 years.
- ECOG performance status >2.
- Predominant histology (>50% of specimen) involves non-urothelial cell carcinoma.
- Prior partial cystectomy.
- Prior pelvis surgery that obviates a completed extended lymphadenectomy (e.g., aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised.
- Contraindications to FDG PET-CT.
- Inability to lie supine for imaging with PET-CT.
- Inadequate hepatic function: (i) Bilirubin >1.5 X ULN and (ii) SGOT and Alkaline phosphatase >3 X ULN
- History of another invasive malignancy within the previous 5 years with the exception of non-melanoma skin cancer.
- Known pregnancy or lactating female.
- Inability to complete the study or required follow-up.
View trial on ClinicalTrials.gov